Quarterly report pursuant to Section 13 or 15(d)

Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details)

v3.23.2
Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue $ 10,412 $ 28,096 $ 23,086 $ 33,993
Collaboration and License Agreements and Supply Agreements        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 10,412 28,096 23,086 33,993
Collaboration and License Agreements and Supply Agreements | Bristol-Myers Squibb Company ("BMS")        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 2,236 2,266 5,402 4,431
Collaboration and License Agreements and Supply Agreements | Merck Sharp & Dohme Corporation ("Merck")        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 140 146 2,693 1,210
Collaboration and License Agreements and Supply Agreements | Merck KGaA, Darmstadt, Germany (operating in the United States and Canada under the name ''EMD Serono'')        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue   137 8 2,034
Collaboration and License Agreements and Supply Agreements | Astellas Pharma Inc. ("Astellas")        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 7,333   13,605  
Collaboration and License Agreements and Supply Agreements | Vaxcyte        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 703 547 1,378 1,318
Collaboration and License Agreements and Supply Agreements | Tasly Biopharmaceuticals Co., Ltd. ("Tasly")        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue   25,000   25,000
BMS Agreement and the 2018 BMS Master Services Agreement        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Revenues 2,236 2,266 5,402 4,431
BMS Agreement and the 2018 BMS Master Services Agreement | Research and Development Services        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Revenues 192 240 413 484
BMS Agreement and the 2018 BMS Master Services Agreement | Materials Supply        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Revenues 2,044 2,026 4,989 3,947
2020 Merck Master Services Agreement        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 140 146 2,693 1,210
2020 Merck Master Services Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue       862
2020 Merck Master Services Agreement | Research and Development Services        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 79 93 204 266
2020 Merck Master Services Agreement | Materials Supply        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 61 53 2,489 82
2019 EMD Serono Supply Agreement        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue   137 8 2,034
2019 EMD Serono Supply Agreement | Research and Development Services        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue   132 6 416
2019 EMD Serono Supply Agreement | Materials Supply        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue   5 2 1,618
Supply Agreement | Vaxcyte        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 703 547 1,378 1,318
Supply Agreement | Vaxcyte | Research and Development Services        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 567 542 1,071 1,143
Supply Agreement | Vaxcyte | Materials Supply        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 136 $ 5 307 $ 175
Astellas License and Collaboration Agreement        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 7,333   13,605  
Astellas License and Collaboration Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 3,239   5,811  
Astellas License and Collaboration Agreement | Research and Development Services        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 1,562   2,719  
Astellas License and Collaboration Agreement | Financing Component on Unearned Revenue        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue $ 2,532   $ 5,075